External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial.

Journal: European urology oncology
PMID:

Abstract

BACKGROUND: Accurate risk stratification is critical to guide management decisions in localized prostate cancer (PCa). Previously, we had developed and validated a multimodal artificial intelligence (MMAI) model generated from digital histopathology and clinical features. Here, we externally validate this model on men with high-risk or locally advanced PCa treated and followed as part of a phase 3 randomized control trial.

Authors

  • Ashley E Ross
    University of Cincinnati, Department of Chemistry, 312 College Drive, 404 Crosley Tower, Cincinnati, Ohio 45221-0172, United States.
  • Jingbin Zhang
    Artera, Inc., Los Altos, CA.
  • Huei-Chung Huang
    Artera, Inc., Los Altos, CA.
  • Rikiya Yamashita
    Artera, Inc., Los Altos, CA.
  • Jessica Keim-Malpass
    Artera, Santa Barbara, CA.
  • Jeffry P Simko
    Department of Radiation Oncology, University of California, San Francisco, San Francisco.
  • Sandy DeVries
    NRG Oncology Biospecimen Bank, University of California, San Francisco, San Francisco.
  • Todd M Morgan
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.
  • Luis Souhami
    Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada.
  • Michael C Dobelbower
    University of Alabama at Birmingham, Department of Radiation Oncology, Birmingham, Alabama.
  • L Scott McGinnis
    Novant Health Presbyterian Medical Center, Charlotte, NC, USA.
  • Christopher U Jones
    Sutter Medical Center Sacramento, Sacramento, CA, USA.
  • Robert T Dess
    University of Michigan, Ann Arbor, MI, USA.
  • Kenneth L Zeitzer
    Albert Einstein Medical Center, Philadelphia, PA, USA.
  • Kwang Choi
    Brooklyn MB-CCOP/SUNY Downstate, Brooklyn, NY, USA.
  • Alan C Hartford
    Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.
  • Jeff M Michalski
    Washington University School of Medicine, Saint Louis, MO, USA.
  • Adam Raben
    Christiana Care Health Services, Inc. CCOP, Wilmington, DE, USA.
  • Leonard G Gomella
    Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • A Oliver Sartor
    Tulane University Health Sciences Center, New Orleans, LA, USA.
  • Seth A Rosenthal
    Sutter General Hospital, accruals for Radiological Associates of Sacramento, Sacramento, California.
  • Howard M Sandler
    Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Daniel E Spratt
    Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland.
  • Stephanie L Pugh
    NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania.
  • Osama Mohamad
    Department of Radiation Oncology, University of California, San Francisco, San Francisco.
  • Andre Esteva
    Artera, Inc., Los Altos, CA.
  • Emmalyn Chen
    Artera, Inc., Los Altos, CA.
  • Edward M Schaeffer
    Department of Urology, Northwestern University Feinberg School of Medicine, Chicago.
  • Phuoc T Tran
    Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore.
  • Felix Y Feng
    Department of Radiation Oncology, University of California, San Francisco, San Francisco.